Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study)

BACKGROUND: Osimertinib is a standard treatment option for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). However, osimertinib monotherapy yields poor clinical outcomes in some patients, necessitating the development of novel treatment strategies. In ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawachi, Hayato, Yamada, Tadaaki, Yoshimura, Akihiro, Morimoto, Kenji, Iwasaku, Masahiro, Tokuda, Shinsaku, Kim, Young Hak, Shimose, Takayuki, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272699/
https://www.ncbi.nlm.nih.gov/pubmed/37333903
http://dx.doi.org/10.1177/17588359231177022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272699/
https://www.ncbi.nlm.nih.gov/pubmed/37333903
http://dx.doi.org/10.1177/17588359231177022

Ejemplares similares